SERUM PANELS USED FOR STUDIES
SERUM SUPPLIED BY VACCINE COMPONENTS
1. ALAN HAMPSON ADULTS A/NEW CALEDONIA/20/99 (H1N1)
WHO, MELBOURNE ELDERLY A/PANAMA/2007/99 (H3N2)
AUSTRALIA B/JOHANNESBURG/5/99
2. JOHN WOOD, PH.D. ADULTS A/NEW CALEDONIA/20/99 (H1N1)
NIBSC, LONDON ELDERLY A/PANAMA/2007/99 (H3N2)
ENGLAND B/GUANGDONG/120/2000
3. S. GRAVENSTEIN, M.D. ADULTS A/NEW CALEDONIA/20/99 (H1N1)
EASTERN VIRGINIA ELDERLY A/PANAMA/2007/99 (H3N2)
MEDICAL SCHOOL B/VICTROIA/504/2000
4. TAKATO ODIGARI, PH.D. ADULTS A/NEW CALEDONIA/20/99 (H1N1)
NIH, TOKYO ELDERLY A/PANAMA/2007/99 (H3N2)
JAPAN B/JOHANNESBURG/5/99
ANTIGENS FOR SEROLOGIES
H1N1
A/NEW CALEDONIA/20/99 *
A/HUBEI/288/2001
A/BANGKOK/255/2001
A/HAWAII/15/2001
A/WISCONSIN/12/2001
A/BRAZIL/821/2001
A/HONG KONG/747/2001
A/FUJIAN/156/2000
A/AUCKLAND/65/2001
A/CHRISTCHURCH/4/2001
* = VACCINE STRAIN
HEMAGGLUTINATION INHIBITION ANTIBODY TITERS TO
INFLUENZA A (H1N1) VIRUSES
|
TRIAL |
TEST SITE |
VIRUS STRAIN |
GMT PRE POST |
%>32or40 PRE POST |
% 4 FOLD RISE |
||
|
USA ADULTS N=24 |
CDC |
A/N’CALEDONIA/20/99* A/BRAZIL/821/2001A/HONG KONG/747/2001 A/AUCKLAND/65/2001 |
21 29 31 14 |
92 127 120 46 |
33 54 54 29 |
88 96 96 71 |
42 42 42 42 |
|
*IVR-116 STRAIN |
|||||||
|
CBER |
A/N’CALEDONIA/20/99* A/HUBEI/288/2001 A/BANGKOK/255/2001 A/HAWAII/15/2001 A/WISCONSIN/12/2001 |
20 24 20 <10 11 |
59 78 48 22 31 |
42 33 33 25 25 |
75 75 71 58 63 |
42 54 42 42 42 |
|
|
*IVR-116 STRAIN |
|||||||
HEMAGGLUTINATION INHIBITION ANTIBODY TITERS TO INFLUENZA
A (H1N1) VIRUSES
| TRIAL |
TEST SITE |
VIRUS STRAIN |
GMT PRE POST |
%>32or40 PRE POST |
% 4 FOLD RISE |
||
|
AUS ELDERLY N=24 |
CDC |
A/N’CALEDONIA/20/99* A/HUBEI/288/2001 A/BANGKOK/255/2001 A/ WISCONSIN/12/2001 A/HAWAII/15/2001 |
8 9 7 9 7 |
44 41 26 40 23 |
8 8 4 13 4 |
70 65 43 61 48 |
63 71 63 71 50 |
|
* IVR-116 STRAIN |
|||||||
|
|
CBER |
A/N’CALEDONIA/20/99* A/HUBEI/288/2001 A/BANGKOK/255/2001 A/ WISCONSIN/12/2001 A/HAWAII/15/2001 |
10 12 <10 15 10 |
52 65 53 53 36 |
21 29 17 38 8 |
75 83 83 75 67 |
72 76 84 56 63 |
|
* IVR-116 STRAIN |
|||||||
ANTIGENS FOR SEROLOGIES
H3N2
A/PANAMA/2007/99 *
A/ARGENTINA/3759/2001
A/PHILIPPINES/78890/2001
A/SINGAPORE/26/2001
A/SINGAPORE/15/2001
A/SOUTH AUSTRALIA/102/2001
A/CHILE/6416/2001
A/HONG KONG/762/2001
A/HAWAII/21/2001
A/ALASKA/14/2001
A/DARWIN/3/2000
A/FUJIAN/140/2000
* = VACCINE STRAIN
HEMAGGLUTINATION INHIBITION ANTIBODY TITERS TO
INFLUENZA A (H3N2) VIRUSES
| TRIAL |
TEST SITE |
VIRUS STRAIN |
GMT PRE POST |
>32or40 PRE POST |
% 4 FOLD RISE |
||
|
EUROPE ADULTS
N=24 |
CDC |
A/PANAMA/2007/99* AHONG KONG/762/2001 A/CHILE/6416/2001 A/HAWAII/21/2001 A/SINGAPORE/15/2001 |
9 12 7 12 6 |
165 120 58 261 39 |
13 13 4 21 0 |
100 100 79 100 71 |
100 96 96 96 88 |
|
* RESVIR 17 STRAIN |
|||||||
|
|
CBER |
A/PANAMA/2007/99* A/SINGAPORE/26/2001 A/DARWIN/3/2000 A/FUJIAN/140/2000 A/CHILE/6416/2001 |
<10 <10 <10 <10 <10 |
101 62 22 53 39 |
0 0 4 4 0 |
88 88 50 67 63 |
92 92 54 83 79 |
|
* RESVIR 17 STRAIN |
|||||||
HEMAGGLUTINATION INHIBITION ANTIBODY TITERS TO
INFLUENZA A (H3N2) VIRUSES
| TRIAL |
TEST SITE |
VIRUS STRAIN |
GMT PRE POST |
%>32or40 PRE POST |
% 4 FOLD RISE |
||
|
USA ELDERLY
N=24 |
CDC |
A/PANAMA/2007/99* A/S AUSTRALIA/102/2001 A/PHILIPPINES/78890/01 A/ALASKA/2001 A/ARGENTINA/3759/2001 |
12 12 22 36 10 |
24 21 41 67 19 |
17 13 33 58 17 |
42 33 67 92 33 |
17 13 13 25 21 |
|
* RESVIR 17 STRAIN |
|||||||
|
|
CBER |
A/PANAMA/2007/99* A/PHILIPPINES/78890/01 A/ARGENTINA/3759/01 |
13 13 14 |
39 19 68 |
29 46 29 |
71 43 88 |
46 33 58 |
|
* RESVIR 17 STRAIN |
|||||||
ANTIGENS FOR SEROLOGIES
B
B/JOHANNESBURG/5/99 * **
B/GUANGDONG/120/2000 * **
B/VICTORIA/504/2000 * **
B/SICHUAN/379/99 **
B/SHIZUOKA/15/2001**
B/TEXAS/22/2001**
B/HONG KONG/692/2001 **
B/SICHUAN/317/2001 **
B/WUHAN/02/2001 **
B/SINGAPORE/1/2001 **
B/BRAZIL/952/2001 **
B/SHIZUOKA/480/2000 **
B/BRAZIL/956/2000 **
B/JOHANNESBURG/69/2001 **
B/HAWAII/10/2001 ** !
B/HONG KONG/330/2001** !
* = VACCINE STRAIN
** = ETHER TREATED
! = B/BEIJING/243/97-LIKE
HEMAGGLUTINATION INHIBITION ANTIBODY TITERS TO
INFLUENZA B VIRUSES
| TRIAL |
TEST SITE |
VIRUS STRAIN |
GMT PRE POST |
%>32or40 PRE POST |
% 4 FOLD RISE |
||
|
USA ADULTS N=24 |
CDC |
B/VICTORIA/504/2000 B/SICHUAN/317/2001 B/TEXAS/22/2001 B/HONG KONG/692/01 B/JO’BURG/69/2001 |
44 36 34 32 18 |
143 110 110 104 52 |
71 63 54 50 25 |
92 92 88 92 71 |
38 38 38 38 33 |
|
|
CBER |
B/VICTORIA/504/2000 B/SHIZUOKA/15/2001 B/TEXAS/22/2001 B/HONG/KONG/692/01 B/SICHUAN/317/2001 B/HONG KONG/330/01 |
60 32 32 29 23 11 |
176 99 93 78 58 38 |
67 54 54 54 50 29 |
88 79 79 79 79 38 |
42 42 46 42 29 8 |
HEMAGGLUTINATION INHIBITION ANTIBODY TITERS TO
INFLUENZA B VIRUSES
| TRIAL |
TEST SITE |
VIRUS STRAIN |
GMT PRE POST |
%>32or40 PRE POST |
% 4 FOLD RISE |
||
|
AUS ELDERLY
N=24 |
AUS |
B/VICTORIA/504/2000 B/BRAZIL/956/2001 B/WUHAN/02/2001 B/SHIZUOKA/15/2001 B/HONG KONG/330/01 B/HAWAII/10/2001 |
15 24 12 23 10 10 |
95 143 67 138 24 22 |
25 38 21 29 17 13 |
88 92 79 92 54 54 |
71 63 67 58 42 38 |
|
|
CBER |
B/GUANGDONG/120/00 B/SHIZUOKA/15/2001 B/TEXAS/22/2001 B/HONG KONG/692/01 B/SICHUAN/317/2001 B/HONG KONG/330/01 |
12 10 <10 <10 <10 <10 |
100 116 76 71 71 <10 |
21 21 21 13 17 17 |
75 79 79 71 71 17 |
68 76 71 68 64 8 |
A/NEW CALEDONIA/20/99 VACCINES
|
H1N1 VIRUSES |
VIRUSES WITH > 50% REDUCTION IN POST-VACCINE GMT NUMBER LOW/NUMBER TESTED |
PER CENT REDUCTION MEAN (RANGE) |
|||||
|
CBER |
CDC |
TOTAL |
|||||
|
A/HAWAII/15/2001 |
5/6 |
2/4 |
7/10 |
60 (31-82) |
|||
|
A/WISCONSIN/12/2001 |
1/6 |
0/4 |
1/10 |
22 (0-70) |
|||
|
A/HUBEI/288/2001 |
0/6 |
0/4 |
0/10 |
6 (0-27) |
|||
|
A/BANGKOK/255/2001 |
0/6 |
0/4 |
0/10 |
30 (0-45) |
|||
|
A/AUCKLAND/65/2001 |
1/3 |
4/6 |
5/9 |
46 (0-93) |
|||
|
A/BRAZIL/821/2001 |
ND |
0/6 |
0/6 |
0 (0) |
|||
|
A/CHRISTCHURCH/4/2001 |
0/3 |
ND |
0/3 |
6 (0-17) |
|||
|
ND= NO DATA |
|||||||
A/PANAMA/2007 VACCINES
|
H3N2 VIRUSES |
VIRUSES WITH > 50% REDUCTION IN POST-VACCINE GMT NUMBER LOW/NUMBER TESTED |
PER CENT REDUCTION MEAN (RANGE) |
|||||
|
CBER |
CDC |
TOTAL |
|||||
|
A/CHILE/6416/2001 |
4/4 |
3/6 |
7/10 |
48 (0-76) |
|||
|
A/ARGETNTINA/3759/2001 |
0/6 |
0/8 |
0/14 |
19 (0-38) |
|||
|
A/PHILIPPINES/78890/2001 |
5/6 |
0/6 |
5/12 |
31 (0-76) |
|||
|
A/HAWAII/21/2001 |
ND |
0/6 |
0/6 |
0 (0) |
|||
|
A/SINGAPORE/15/2001 |
ND |
6/6 |
6/6 |
71 (64-76) |
|||
|
A/ SINGAPORE/26/2001 |
0/4 |
ND |
0/4 |
34 (22-41) |
|||
|
A/S AUSTRALIA/102/2001 |
ND |
2/8 |
2/8 |
35 (17-59) |
|||
|
ND= NO DATA |
|||||||
B/SICHUAN/379/99-LIKE VACCINES
|
B VIRUSES |
VIRUSES WITH > 50% REDUCTION IN POST-VACCINE GMT NUMBER LOW/NUMBER TESTED |
PER CENT REDUCTION
|
|||||
|
CBER |
CDC |
TOTAL |
MEAN (RANGE) |
||||
|
B/TEXAS/22/2001 |
0/6 |
1/8 |
1/14 |
21 (0-77) |
|||
|
B/HONG KONG/692/2001 |
1/6 |
0/8 |
1/14 |
22 (0-56) |
|||
|
B/SHIZUOKA/15/2001 |
0/6 |
0/4 |
0/10 |
8 (0-44) |
|||
|
B/SICHUAN/317/2001 |
1/6 |
0/8 |
1/14 |
25 (0-67) |
|||
|
B/HAWAII/10/2001 |
4/4 |
4/4 |
8/8 |
62 (50-94) |
|||
|
B/HONG KONG/330/2001 |
6/6 |
4/4 |
10/10 |
74 (58-96) |
|||
|
ND= NO DATA |
ETHER TREATED ANTIGEN |
||||||